For women with ductal carcinoma in situ (DCIS), adding radiation therapy and/or tamoxifen to treatment lowers the risk of the recurrence of aggressive cancer, doctors at Allegheny General Hospital and the National Surgical Adjuvant Breast Bowel Project revealed in the Journal of the National Cancer Institute.
Women with ductal carcinoma in situ—DCIS—who later develop invasive breast cancer in the same breast are at higher risk of dying from breast cancer than those who do not develop invasive disease, according to a study published online March 11 in the Journal of the National Cancer Institute.
New findings published in Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research, confirm the risk of breast cancer among women who are obese and not physically active, and suggests additional mechanisms beyond estrogen.
Women with an aggressive type of early-stage breast cancer (HER2-positive disease) given trastuzumab (Herceptin) for one year following standard chemotherapy are at significantly less risk of the cancer returning, and the effect is long lasting, according to the long-term results of the landmark HERA trial published Online First in The Lancet Oncology.
A rare but hard-to-treat form of breast cancer is driven by a newly discovered gene, researchers have found.